Rise in prices of Raw Materials for Pharma industry

The hike in the prices of petroleum products has caused a steep rise in the prices of raw materials required for the pharma industry which faces acute shortage of active pharmaceutical ingredients (APIs) for formulation development and intermediates for APIs.

A large number of APIs and other materials for pharmaceutical products are manufactured from petroleum goods, and now the industry faces difficult to make large quantity of pharmaceuticals targeting global market because of the price rise.

“There are so many materials made from petrochemicals in pharma industry. Acetylsalicylic acid (ASA), the key element in various OTC pain medications, preparatory substances like phenol and cumene used for manufacturing penicillin and aspirin, plastic components for manufacturing bottles for keeping vaccines, blood, disposable syringes, resins used in drug purification procedures etc are sourced petroleum products.

The prices of all these products have increased by 50 to 100 per cent now,” says Himanshu Shah, president of the MP Small Scale Drugs Manufacturers Association (MPSDMA).”

 

Further, the manufacturers face drastic shortages of APIs which are imported mostly from other countries. Under the pretext of promoting API production in India, the government has increased the customs duty also.

Industry sources are of the opinion that the government must give all possible support to the domestic drug makers to import sufficient raw materials from abroad until the country becomes self-sufficient in API production.

According to industry sources from other states, the drop in the import of raw materials mainly from China has hit the total pharma MSMEs and the situation has increased the prices of the available raw materials.

Speaking to the issues that led the industry into crisis, Himanshu Shah said even in this critical situation the government is imposing penalties on manufacturers for delayed supplies citing liquidated damages (LD).

He said the industry cannot procure raw materials on time and cannot afford their prices. Even then, the manufacturers in the MSME sector operate their factories and work hard to fulfill the requirement of the government.

But, if one or two days delayed, the authorities impose penalty on them. He wanted the government to give some relaxations to the industry during this critical time and exempt them from penalties for any so called LDs.

Related Posts

Indian Pharma Majors Plan to Invest in US

National Harbor (US): Top Indian pharmaceutical companies, including at least three from Hyderabad, are all set to announce major investments to set up new facilities in the United States during…

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Emcure Pharmaceuticals Ltd on Tuesday reported a 24 per cent increase in consolidated net profit at ₹243.74 crore in the fourth quarter ended March 2026 on the back of robust…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Indian Pharma Majors Plan to Invest in US

Indian Pharma Majors Plan to Invest in US

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Fake Cancer Drug Racket: Delhi HC Grants Bail, Flags Gaps in ED Probe

Fake Cancer Drug Racket: Delhi HC Grants Bail, Flags Gaps in ED Probe

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification